AMRN Amarin Corp

    RNS Number : 5806Y
  Amarin Corporation Plc
  08 July 2008
   

    

    AMARIN NOTICE OF ANNUAL GENERAL MEETING 

    DUBLIN, Ireland, July 8, 2008 - Amarin Corporation plc (NASDAQ: AMRN) announced today it has sent to its shareholders a Notice of the
Annual General Meeting of the Company, which will be held on July 31, 2008.  

    Copies of the Notice, together with the Company's Annual Report for the year ended December 31, 2007 and the proposed new Articles of
Association of the Company referred to in the Notice are available on the Company's website at www.amarincorp.com. Shareholders may receive
a hard copy of the Annual Report and the proposed new Articles of Association of the Company free of charge by contacting Investor Relations
at the Company on +353 1669 9020 or investor.relations@amarincorp.com.

    Amarin's Annual Report for the year ended December 31, 2007 on Form 20-F was filed with the U.S. Securities and Exchange Commission on
May 19, 2008.

    About Amarin
    Amarin is a biopharmaceutical company focused on improving the lives of patients suffering from cardiovascular and central nervous
system (CNS) diseases. Amarin's cardiovascular programs capitalize on the known therapeutic benefits of essential fatty acids in
cardiovascular disease. Amarin's CNS development pipeline includes programs in myasthenia gravis, Huntington's disease, Parkinson's disease,
epilepsy and memory. Amarin also has two proprietary technology platforms: a lipid-based technology platform for the targeted transport of
molecules through the liver and/or to the brain, and a unique mRNA technology based on cholinergic neuromodulation. Amarin has its primary
stock market listing in the U.S. on the NASDAQ Capital Market ("AMRN").


    Contacts: 
    Amarin +353 (0)1 669 9020 
    Thomas Lynch, Chairman and Chief Executive Officer
    Alan Cooke, President and Chief Operating Officer
    Darren Cunningham, EVP Strategic Development and Investor Relations
    investor.relations@amarincorp.com 

    Disclosure Notice 
    The information contained in this document is as of July 8, 2008. Amarin assumes no obligation to update any forward-looking statements
contained in this document as a result of new information or future events or developments. This document contains forward-looking
statements about Amarin's financial condition, results of operations, business prospects and products in research that involve substantial
risks and uncertainties. You can identify these statements by the fact that they use words such as "will", "anticipate", "estimate",
"expect", "project", "forecast", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion
of future operating or financial performance or events. Among the factors that could cause actual results to differ materially from those
described or projected herein are the following: Amarin's ability to maintain sufficient cash and other liquid resources to meet its
operating and debt service requirements; the success of Amarin's research and development activities; decisions by regulatory authorities regarding whether and when to approve Amarin's drug applications, as
well as their decisions regarding labeling and other matters that could affect the commercial potential of Amarin's products; the speed with
which regulatory authorizations, pricing approvals and product launches may be achieved; the success with which developed products may be
commercialized; competitive developments affecting Amarin's products under development; the effect of possible domestic and foreign
legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including under Medicaid and
Medicare in the United States, and involuntary approval of prescription medicines for over-the-counter use; Amarin's ability to protect its
patents and other intellectual property; claims and concerns that may arise regarding the safety or efficacy of Amarin's product candidates;
governmental laws and regulations affecting Amarin's operations, including those affecting taxation; risks relating to the Company's ability to maintain its Nasdaq listing; general changes in
International Financial Reporting Standards; and growth in costs and expenses. A further list and description of these risks, uncertainties
and other matters can be found in Amarin's Form 20-F for the fiscal year ended December 31, 2007, filed with the SEC on May 19, 2008.

    
    This announcement has been issued through the Companies Announcement Service of the Irish Stock Exchange


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
ISERPMBTMMAMBJP

Amarin (LSE:AMRN)
Historical Stock Chart
From Apr 2024 to May 2024

Amarin (LSE:AMRN)
Historical Stock Chart
From May 2023 to May 2024